At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care.
- Two therapeutic areas – Haematology and Immunology – and a portfolio of products within Specialty Care
- Our extended half-life factor replacement treatments are the most prescribed treatments for haemophilia - A and B respectively in several markets
- A strong portfolio of on-market products, and an extensive portfolio of pre-market assets
- An international biopharmaceutical company covering the entire value chain
- We put our focus where we can have the greatest impact, in late-stage research and development, and in patient access and commercialisation
2010
Served areaWorldwide
Headcount1,509
HeadquartersTomtebodavägen 23A, 17165 Solna – Sweden
Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Assets | N/A | 48,283,000,000.00 | 48,661,000,000.00 | 52,496,000,000.00 |
Noncurrent Assets | N/A | 40,115,000,000.00 | 39,883,000,000.00 | 41,285,000,000.00 |
Property Plant And Equipment | N/A | 534,000,000.00 | 493,000,000.00 | 274,000,000.00 |
Deferred Tax Assets | N/A | 611,000,000.00 | 767,000,000.00 | 877,000,000.00 |
Current Assets | N/A | 8,168,000,000.00 | 8,778,000,000.00 | 11,210,000,000.00 |
Inventories | N/A | 3,053,000,000.00 | 3,424,000,000.00 | 3,332,000,000.00 |
Current Trade Receivables | N/A | 3,756,000,000.00 | 3,439,000,000.00 | 5,249,000,000.00 |
Other Current Receivables | N/A | 465,000,000.00 | 345,000,000.00 | 558,000,000.00 |
Cash and cash equivalents | 737,000,000.00 | 404,000,000.00 | 1,045,000,000.00 | 1,361,000,000.00 |
Equity And Liabilities | N/A | 48,283,000,000.00 | 48,661,000,000.00 | 52,496,000,000.00 |
Equity | N/A | 20,206,000,000.00 | 23,203,000,000.00 | 26,525,000,000.00 |
Issued Capital | N/A | 167,000,000.00 | 169,000,000.00 | N/A |
Issued Capital Ordinary Shares | N/A | N/A | 169,000,000.00 | 170,000,000.00 |
Retained Earnings Profit Loss For Reporting Period | N/A | N/A | 2,679,000,000.00 | 2,638,000,000.00 |
Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | 10,476,000,000.00 | 13,155,000,000.00 |
Other Reserves | N/A | -253,000,000.00 | -66,000,000.00 | 351,000,000.00 |
Additional Paidin Capital | N/A | 9,816,000,000.00 | 9,945,000,000.00 | 10,211,000,000.00 |
Equity Attributable To Owners Of Parent | N/A | 20,206,000,000.00 | 23,203,000,000.00 | 26,525,000,000.00 |
Noncurrent Liabilities | N/A | 17,634,000,000.00 | 16,697,000,000.00 | 11,114,000,000.00 |
Noncurrent Provisions | N/A | 252,000,000.00 | 234,000,000.00 | N/A |
Deferred Tax Liabilities | N/A | 3,464,000,000.00 | 3,605,000,000.00 | 3,797,000,000.00 |
Other Noncurrent Financial Liabilities | N/A | 3,473,000,000.00 | 3,834,000,000.00 | 3,899,000,000.00 |
Longterm Borrowings | N/A | 10,137,000,000.00 | 8,777,000,000.00 | 2,971,000,000.00 |
Current Liabilities | N/A | 10,443,000,000.00 | 8,761,000,000.00 | 14,857,000,000.00 |
Current Provisions | N/A | N/A | 267,000,000.00 | 499,000,000.00 |
Trade And Other Current Payables To Trade Suppliers | N/A | 569,000,000.00 | 558,000,000.00 | 1,252,000,000.00 |
Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 4,700,000,000.00 | 5,253,000,000.00 |
Current Tax Liabilities Current | N/A | 518,000,000.00 | 40,000,000.00 | 23,000,000.00 |
Other Current Liabilities | N/A | 1,302,000,000.00 | 1,314,000,000.00 | 1,900,000,000.00 |
Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 4,015,000,000.00 | 1,768,000,000.00 | 5,796,000,000.00 |
Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
---|---|---|---|
Revenue | 15,261,000,000.00 | 15,529,000,000.00 | N/A |
Revenue From Contracts With Customers | N/A | 15,529,000,000.00 | 18,790,000,000.00 |
Other Income | 401,000,000.00 | 32,000,000.00 | 34,000,000.00 |
Profit Loss From Operating Activities | 4,818,000,000.00 | 3,733,000,000.00 | 3,813,000,000.00 |
Finance Income | 1,000,000.00 | 16,000,000.00 | 5,000,000.00 |
Finance Costs | 602,000,000.00 | 454,000,000.00 | 497,000,000.00 |
Profit Loss Before Tax | 4,217,000,000.00 | 3,295,000,000.00 | 3,321,000,000.00 |
Income Tax Expense Continuing Operations | 972,000,000.00 | 616,000,000.00 | 683,000,000.00 |
Profit (loss) | 3,245,000,000.00 | 2,679,000,000.00 | 2,638,000,000.00 |
Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Profit (loss) | N/A | 3,245,000,000.00 | 2,679,000,000.00 | 2,638,000,000.00 |
Adjustments For Decrease Increase In Inventories | N/A | -1,325,000,000.00 | -318,000,000.00 | 413,000,000.00 |
Other Adjustments For Noncash Items | N/A | 390,000,000.00 | 529,000,000.00 | 741,000,000.00 |
Interest Paid Classified As Operating Activities | N/A | 333,000,000.00 | 324,000,000.00 | 309,000,000.00 |
Interest Received Classified As Operating Activities | N/A | 1,000,000.00 | 0.00 | 5,000,000.00 |
Income Taxes Paid Refund Classified As Operating Activities | N/A | N/A | 1,124,000,000.00 | 673,000,000.00 |
Cash Flows From Used In Operating Activities | N/A | 4,926,000,000.00 | 5,470,000,000.00 | 4,665,000,000.00 |
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 8,000,000.00 | 3,000,000.00 | 0.00 |
Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 41,000,000.00 | 47,000,000.00 | 72,000,000.00 |
Purchase Of Intangible Assets Classified As Investing Activities | N/A | 3,811,000,000.00 | 323,000,000.00 | 1,405,000,000.00 |
Cash Flows From Used In Investing Activities | N/A | -3,964,000,000.00 | -367,000,000.00 | -1,477,000,000.00 |
Proceeds From Borrowings Classified As Financing Activities | N/A | 13,575,000,000.00 | 14,193,000,000.00 | 13,675,000,000.00 |
Repayments Of Borrowings Classified As Financing Activities | N/A | 15,027,000,000.00 | 18,191,000,000.00 | 16,094,000,000.00 |
Payments Of Lease Liabilities Classified As Financing Activities | N/A | 118,000,000.00 | 125,000,000.00 | 133,000,000.00 |
Cash Flows From Used In Financing Activities | N/A | -1,282,000,000.00 | -4,474,000,000.00 | -2,991,000,000.00 |
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -320,000,000.00 | 629,000,000.00 | 197,000,000.00 |
Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -13,000,000.00 | 12,000,000.00 | 119,000,000.00 |
Cash and cash equivalents | 737,000,000.00 | 404,000,000.00 | 1,045,000,000.00 | 1,361,000,000.00 |
Please note that some sums might not add up.
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
14.09.23 | Anders Ullman | Other | Other | SEK 60,918.00 |
09.08.23 | Mats Lek | Other | Buy | SEK 20,309.79 |
09.08.23 | Linda Therese Larsson | Other | Buy | SEK 19,895.30 |
09.06.23 | Henrik Stenqvist | Other | Other | SEK 0.00 |
16.05.23 | Bo Jesper Hansen | Other | Buy | SEK 3,401,897.04 |
16.05.23 | Bo Jesper Hansen | Other | Buy | SEK 1,635,256.80 |
16.05.23 | Bo Jesper Hansen | Other | Buy | SEK 399,865.80 |
16.05.23 | Bo Jesper Hansen | Other | Buy | SEK 131,646.00 |
16.05.23 | Bo Jesper Hansen | Other | Buy | SEK 122,942.60 |
16.05.23 | Bo Jesper Hansen | Other | Buy | SEK 5,227.20 |
SE0000872095
LEI549300124Y3MQI87PT35
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.